search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Joint bleeds in Von Willebrand disease: Impact on joint integrity, -function and daily life.


- candidate number17556
- NTR NumberNTR4548
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR23-apr-2014
- Secondary IDsNL38989.041.12 
- Public TitleJoint bleeds in Von Willebrand disease: Impact on joint integrity, -function and daily life.
- Scientific TitleArthropathy in patients with congenital severe and moderate severe Von Willebrand disease
- ACRONYMWillebrand Artropathy Study
- hypothesisthe severity and impact of arthropathy in patients with VWD could be significant
- Healt Condition(s) or Problem(s) studiedVon Willebrand Disease, Joint
- Inclusion criteriaPatients with moderate or severe VWD treated with coagulation factor or desmopressin for 1 or more joint bleeds as documented in their MF.

A similar size control group of age (< 2 years difference), FVIII and sex matched moderate or severe VWD patients who participated in the WiN study, indicated that they would like to participate in future studies, and did not report treatment for 1 or more joint bleeds and also did not have joint bleeds recorded in their MF.
Also eligible for the control group are moderate or severe VWD patients who did not participate in the WiN study and are currently treated at the haemophilia treatment centres in the Netherlands who have not been treated with coagulation factor or desmopressin for 1 or more joint bleeds and without joint bleeds treatment documented in their MF.
- Exclusion criteriaInability of the patient or the patients parents to give informed consent
A recent joint bleed without complete recovery
Restricted motion of an ankle, knee or elbow joint for another medical reason
No medical file available
Age<4 years
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- groupParallel
- Type2 or more arms, non-randomized
- Studytypeobservational
- planned startdate 12-aug-2013
- planned closingdate30-jan-2015
- Target number of participants100
- Interventionsassessment of joint damage, joint pain and related functional and social impairment by 4 questionnaires for adults, 1 for children, 1 physical joint examination, joint X-rays and 1 functional test. The physical joint examination and functional test will be scored by an experienced physiotherapist using the Haemophilia Joint Health Score (HJHS). The functional test consists of a figure 8 walking test. X-rays will be taken of affected and contralateral joints in all participants aged>12 years and of the same joint in a matched control patient.
- Primary outcomeExistence of arthropathy: the number and percentage of patients with arthropathy among the different patient groups. Severity of arthropathy: separate and cumulative scores of HJHS and Pettersson. Impact of arthropathy on physical functioning and participation: time to complete the figure 8 walking test, separate and cumulative scores of (Ped)HAL and IPA questionnaires. Impact on quality of life: separate and cumulative scores of D-AIMS2-affect and MPQ-DLV questionnaires.
- Secondary outcomeInfluence of the severity of the coagulation defect on the existence, severity and impact of arthropathy Number and sites of affected joints Quantitative use of desmopressin and coagulation factors in relation to the existence of arthropathy Prophylactic use of coagulation factors in relation to the existence of arthropathy
- Timepointsone assessment no follow up assessments planned
- Trial web site
- statusinclusion stopped: follow-up
- CONTACT FOR PUBLIC QUERIES K.P.M. Galen, van
- CONTACT for SCIENTIFIC QUERIES K.P.M. Galen, van
- Sponsor/Initiator University Medical Center Utrecht (UMCU)
- Funding
(Source(s) of Monetary or Material Support)
CSL Behring
- Publications
- Brief summaryCross sectional multicenter cohort study that investigates the prevalence, severity and impact of arthropathy in patients with moderate and severe Von Willebrand disease and documented treatment of joint bleeds with desmopressin or clotting factor concentrate compared to moderate and severe VWD patients without such documented joint bleed treatment.
- Main changes (audit trail)
- RECORD23-apr-2014 - 26-mei-2014


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl